| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 02/07/2001 | CN1061557C Capsule of ginkgo and garlic extracts |
| 02/07/2001 | CN1061556C Gingko-Ribes burejense capsule |
| 02/07/2001 | CN1061555C Chinese patent drug for treating hypertension |
| 02/06/2001 | US6184382 Process for preparing N6-substituted adenosine derivatives |
| 02/06/2001 | US6184256 Methods and compositions for use in modulating expression of matrix metalloproteinase genes |
| 02/06/2001 | US6184255 Enhanced absorption |
| 02/06/2001 | US6184248 Compositions and methods for treatment of neurological disorders and neurodegenerative diseases |
| 02/06/2001 | US6184244 C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| 02/06/2001 | US6184237 Substituted pyridine compounds and methods of use |
| 02/06/2001 | US6184235 2-phenyl benzimidazole derivatives as MCP-1 antagonists |
| 02/06/2001 | US6184233 Crystals having storage stability, oral absorption, solubility; hypotensive agents, platelet agglutination control agents |
| 02/06/2001 | US6184231 3-substituted-4-arylquinolin-2-one derivatives as potassium channel modulators |
| 02/06/2001 | US6184226 Antiinflammatory agents for treatment of cardiovascular system disorders/respiratory system disorders, antiischemic agents |
| 02/06/2001 | US6184223 Reverse-turn mimetics and methods relating thereto |
| 02/06/2001 | US6184214 Hydrolysis of 2-dichlorophosphoryloxy-acrylonitrile to form 2-hydroxyacrylamide-o-monophosphate; antiischemic agents for treating disorders due to the lack of atp |
| 02/06/2001 | US6184212 Antisense modulation of human mdm2 expression |
| 02/06/2001 | US6183780 May be used for the application of active substances whenever a certain lag-time before release is advantageous, such as in be the case of anti-asthmatics, anti-emetics, cardiotonics, vasodilators, anti-vertigo and anti-meniere. |
| 02/06/2001 | US6183775 Buccal delivery system |
| 02/06/2001 | US6183752 Gene expression of exogenous epitope of cytomegalo virus; genetic engineering |
| 02/06/2001 | CA2315309A1 Process for the preparation in pure form of the protease activating blood clotting factor vii, its proenzyme or a mixture of both proteins by means of affinity chromatography |
| 02/06/2001 | CA2315306A1 Process for the preparation in pure form of the protease activating blood clotting factor vii, its proenzyme or a mixture of both proteins by means of ion-exchange chromatography |
| 02/06/2001 | CA2314798A1 1,2,4,5-tetrahydro-benzo[d]azepin derivatives |
| 02/06/2001 | CA2147807C Bicyclic-aromatic compounds; pharmaceutical and cosmetic compositions containing them and uses |
| 02/06/2001 | CA2106299C Monoclonal and chimeric antibodies specific for human tumor necrosis factor |
| 02/06/2001 | CA2067744C The human c3b/c4b receptor (cr1) |
| 02/05/2001 | CA2314867A1 2,7-substituted octahydro-1h-pyrido¬1,2-a|pyrazine derivatives as ligands for serotonin receptors |
| 02/01/2001 | WO2001007658A1 Abc transport polynucleotides, polypeptides, and antibodies |
| 02/01/2001 | WO2001007628A2 Human synthetases |
| 02/01/2001 | WO2001007612A2 Receptors and associated proteins |
| 02/01/2001 | WO2001007595A2 Novel fibroblast growth factor and nucleic acids encoding same |
| 02/01/2001 | WO2001007568A2 Muscle cells and their use in cardiac repair |
| 02/01/2001 | WO2001007471A2 Cell cycle and proliferation proteins |
| 02/01/2001 | WO2001007470A2 Human nervous system-associated proteins |
| 02/01/2001 | WO2001007459A1 29 human secreted proteins |
| 02/01/2001 | WO2001007453A1 Tricyclic monosaccharide derivatives useful in treating acute ischemia-induced neurodegeneration |
| 02/01/2001 | WO2001007441A1 8-PHENYL-6,9-DIHYDRO-[1,2,4]TRIAZOLO[3,4-i]PURIN-5-ONE DERIVATIVES |
| 02/01/2001 | WO2001007436A2 Substituted oxoazaheterocyclyl compounds |
| 02/01/2001 | WO2001007424A1 2-arylimino-2,3-dihydrothiazoles, and their use thereof as somatostatin receptor ligands |
| 02/01/2001 | WO2001007419A1 Novel thiazine or pyrazine derivatives |
| 02/01/2001 | WO2001007417A1 1,4,5,6-tetrahydropyrimidine derivative as a vitronectin inhibitor |
| 02/01/2001 | WO2001007405A2 New vitamin d derivatives with cyclic substructures in the side chains, method and intermediates for their production and their use in the preparation of medicaments |
| 02/01/2001 | WO2001007072A1 Modulation of platelet activation |
| 02/01/2001 | WO2001007066A2 Ppar delta inhibitors for the treatment of cardiovascular diseases |
| 02/01/2001 | WO2001007057A1 Treatment of angiogenesis dependent conditions with dextrin sulphate |
| 02/01/2001 | WO2001007043A1 Azetidine carboxamide derivatives for the treatment of cns disorders |
| 02/01/2001 | WO2001007023A2 Azetidine compounds in cns and eye diseases |
| 02/01/2001 | WO2001007022A2 Azetidine compounds in cns and eye diseases |
| 02/01/2001 | WO2001007017A1 Transdermal therapeutic system for administering a calcium antagonist |
| 02/01/2001 | WO2001006984A2 Small molecules useful in the treatment of inflammatory disease |
| 02/01/2001 | WO2000063215A3 Indazole derivatives, preparation and therapeutic application thereof |
| 02/01/2001 | WO2000056357A3 Staphylococcus antigen and vaccine |
| 02/01/2001 | WO2000053742A3 Polynucleotides and proteins encoded thereby |
| 02/01/2001 | WO2000053733A3 Hermansky pudlak syndrome protein-interacting proteins and methods of use thereof |
| 02/01/2001 | WO2000050017A3 Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of cerebral diseases |
| 02/01/2001 | WO2000049043A3 Human lipid-associated proteins |
| 02/01/2001 | WO2000040226A3 Method of treating sexual disturbances |
| 02/01/2001 | DE19935771A1 Neue Vitamin D-Derivate mit cyclischen Substrukturen in den Seitenketten, Verfahren und Zwischenprodukte zu ihrer Herstellung und die Verwendung zur Herstellung von Arzneimitteln New vitamin D derivatives with cyclic substructures in the side chains, to processes and intermediates for their preparation and to the use for the preparation of medicaments |
| 02/01/2001 | CA2396591A1 Abc transport polynucleotides, polypeptides, and antibodies |
| 02/01/2001 | CA2383690A1 29 human secreted proteins |
| 02/01/2001 | CA2382755A1 Substituted oxoazaheterocyclyl compounds |
| 02/01/2001 | CA2380317A1 Human synthetases |
| 02/01/2001 | CA2380226A1 Novel fibroblast growth factor and nucleic acids encoding same |
| 02/01/2001 | CA2380218A1 Novel thiazine or pyrazine derivatives |
| 02/01/2001 | CA2380208A1 Tricyclic monosaccharide derivatives useful in treating acute ischemia-induced neurodegeneration |
| 02/01/2001 | CA2380181A1 8-phenyl-6,9-dihydro-¬1,2,4|triazolo¬3,4-i|purin-5-one derivatives |
| 02/01/2001 | CA2379801A1 Receptors and associated proteins |
| 02/01/2001 | CA2379784A1 Cell cycle and proliferation proteins |
| 02/01/2001 | CA2378643A1 Muscle cells and their use in cardiac repair |
| 02/01/2001 | CA2378473A1 Modulation of platelet activation |
| 02/01/2001 | CA2378462A1 Ppar delta inhibitors for the treatment of cardiovascular diseases |
| 02/01/2001 | CA2378395A1 Treatment of angiogenesis dependent conditions with dextrin sulphate |
| 02/01/2001 | CA2376465A1 New vitamin d derivatives with cyclic substructures in the side chains, method and intermediates for their production and their use in the preparation of medicaments |
| 02/01/2001 | CA2375571A1 Human nervous system-associated proteins |
| 01/31/2001 | EP1072609A2 Cytoprotective agents comprising prosaposin-related peptides |
| 01/31/2001 | EP1072597A1 Pyrazoles and their use as endothelin antagonists |
| 01/31/2001 | EP1071781A1 B-cell growth factor related protein |
| 01/31/2001 | EP1071778A2 Srebp-2-deficient cell lines |
| 01/31/2001 | EP1071708A1 Edg family gene, human h218 |
| 01/31/2001 | EP1071707A1 Novel omega conotoxin peptides |
| 01/31/2001 | EP1071702A1 Fatty acid derivatives of bile acids and bile acid derivatives |
| 01/31/2001 | EP1071701A1 Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof |
| 01/31/2001 | EP1071699A1 Enhanced antisense modulation of icam-1 |
| 01/31/2001 | EP1071680A1 N,n-disubstituted amides that inhibit the binding of integrins to their receptors |
| 01/31/2001 | EP1071671A2 Triazolones with a neuroprotective action |
| 01/31/2001 | EP1071670A1 Novel diphenyl-substituted 5-ring-heterocycles, method for producing them and their use as medicaments |
| 01/31/2001 | EP1071655A1 Cubane derivatives as metabotropic glutamate receptor antagonists and process for their preparation |
| 01/31/2001 | EP1071485A2 Revascularization apparatus having coaxial channeling and injection means |
| 01/31/2001 | EP1071455A1 Terminally-branched polymeric linkers and polymeric conjugates containing the same |
| 01/31/2001 | EP1071445A2 Therapeutic angiogenic factors and methods for their use |
| 01/31/2001 | EP1071434A1 Cnre binding factors and uses thereof |
| 01/31/2001 | EP1071430A1 Treatment of iatrogenic and age-related hypertension with vitamin b6 derivatives and pharmaceutical compositions useful therein |
| 01/31/2001 | EP1071428A2 Folic acid-containing pharmaceutical compositions, and related methods and delivery systems |
| 01/31/2001 | EP1071427A1 Intermittent claudication therapeutic drugs comprising pyrroloazepines |
| 01/31/2001 | EP1071426A2 Novel compounds and their use as positive ampa receptor modulators |
| 01/31/2001 | EP1071419A1 Cannabinoids as antioxidants and neuroprotectants |
| 01/31/2001 | EP1071403A1 Pharmaceutical composition containing a statin and aspirin |
| 01/31/2001 | EP1071397A2 Controlled release peroral compositions of levosimendan |
| 01/31/2001 | CN1282337A Cyclopeptide derivatives with integrin inhibitor properties |
| 01/31/2001 | CN1282321A Potassium channel openers |
| 01/31/2001 | CN1282252A Ginkgo biloba leaf extracts with reduced 4'-0-methylpyridoxine and biflavone content |